Edison Expands its European Pharmaceutical Coverage by Initiating on MagForce

Edison Expands its European Pharmaceutical Coverage by Initiating on MagForce

  PR Newswire

  LONDON, November 27, 2013

LONDON, November 27, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm,
announces the initiation of coverage of MagForce (MF6), a German firm with a
European approved nanotechnology-based therapy to treat brain tumours .

 (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Edison's report, Coming out in Force , examines MagForce's ability to execute
on its strategy to increase uptake of its novel NanoTherm therapy, already
approved in Europe for brain cancer. MagForce has worked closely with a number
of key opinion leaders to design a new glioblastoma (GBM) study, starting
imminently, to help increase physician acceptance and awareness of the
therapy. It also intends to enter the US market and develop NanoTherm therapy
for prostate cancer. Edison's risk-adjusted valuation is €197m or €8.2/share.

For the full report see:
http://www.edisoninvestmentresearch.com/research/company/magforce

About Edison Investment Research

The launch of coverage on MagForce is part of a programme of research
initiations on bio-pharmaceutical companies exposed to global market
opportunities. Edison provides detailed research coverage on more than 150
pharmaceutical and healthcare companies in Europe, North America, Australia
and New Zealand. Its team of over 100 analysts and investment professionals
works with leading companies, fund managers and investment banks worldwide to
support its capital markets activity. It provides services to more than 400
retained corporate and investor clients from offices in London, New York,
Frankfurt, Sydney and Wellington. All reports Edison publishes are available
to download free of charge from its website http://www.edisongroup.com .

Edison is authorised and regulated by the Financial Services Authority (
http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584 ). Edison is not
an adviser or broker-dealer and does not provide investment advice. Edison's
reports are not solicitations to buy or sell any securities.

About Magforce

MagForce is a German firm with a European approved nanotechnology-based
therapy to treat brain tumours. NanoTherm therapy consists of nanoparticle
injection into the tumour, activated by an external magnetic field, producing
heat and thermally destroying or sensitising the tumour.

For more information please contact:

Dr Philippa Gardner, Edison Investment Research, +44(0)20-3681-2521
healthcare@edisongroup.com
 
Press spacebar to pause and continue. Press esc to stop.